Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): A melatonin oxidative metabolite

Life Sciences

Volumn 73, Issue 12, 2003, Pages 1587-1597

  Harthé, Catherine ^a   Claudy, Danièle ^a   Déchaud, Henri ^a   Vivien Roels, Berthe ^b   Pévet, Paul ^b   Claustrat, Bruno ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CNRS   (France)

Author keywords

AFMK; AMK; Melatonin; Neurodegenerative disorders; Oxidative stress; RIA

Indexed keywords

MELATONIN; MELATONIN DERIVATIVE; N ACETYL 5 METHOXYKYNURENAMINE; N ACETYL N FORMYL 5 METHOXYKYNURAMINE; TRACER; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BLOOD LEVEL; CHROMATOGRAPHY; MALE; NONHUMAN; OXIDATIVE STRESS; RADIOIMMUNOASSAY; RAT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 0037966074     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00483-1     Document Type: Article

References (15)

1. Abraham G.E., Buster J.E., Lucas L.A., Corrales P.C., Teller R.C. Chromatographic separation of steroid hormones for use in radioimmunoassay. Analytical Letters. 5:1972;509-517.
2. Behrmann G., Hardeland R. Protoporphyrin-mediated photooxidation of melatonin and 5-methoxytryptophol exposed to UV. Hardeland Cellular rhythms and indoleamines. 1995;135-139 Univ of Göttingen.
3. Bowling A.C., Beal M.F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences. 56:1995;1151-1171.
4. Brun J., Claustrat B., Harthe C., Vitte P.A., Cohen R., Chazot G. Melatonin RIA: analytical and physiological criteria of validity. Advances in the Biosciences. vol. 53:1984;41-45.
5. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Annals of the New York Academy of Sciences. 899:2000;112-120.
6. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of Neurology. 32:1992;804-812.
7. Foley P., Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. Journal of Neurology. 247:2000;1182-1194.
8. Hirata F., Hayaishi O., Tokuyama T., Senoh S. In vitro and in vivo formation of two new metabolites of melatonin. The Journal of Biological Chemistry. 249:1974;1311-1313.
9. Kennaway D.J., Hugel H.M., Clarke S., Tjandra A., Johnson D.W., Royles P. Structure-activity studies of melatonin analogues in prepubertal male rats. Australian Journal of Biological Sciences. 41:1988;393-400.
10. Pardridge W.M., Mietus L.J. Transport of albumin-bound melatonin through the blood-brain barrier. Journal of Neurochemistry. 34:1980;1761-1763.
11. Retz W., Gsell W., Munch G., Rösler M., Riederer P. Free radicals in Alzheimer's disease. Journal of Neural Transmission. 54:1998;221-236.
12. Rodden F.A., Berg C.P. Enzymatic conversion of L- and D-tryptophan to kynurenine by rat liver. The Journal of Nutrition. 104:1974;227-238.
13. Scatchard G. The attraction of proteins for small molecules and ions. Annals of the New York Academy of Sciences. 51:1949;660-672.
14. Tan D.X., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine Journal. 1:1993;57-60.
15. Tan D.X., Manchester L.C., Buckhardt S., Sainz R.M., Mayo J.C., Kohen R., Shohami E., Huo Y.S., Hardeland R., Reiter R.J. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, function as a potent antioxidant. The FASEB Journal. 15:2001;2294-2296.